50
total announcements
DRREDDY.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 15 Oct 2026
Market Cap
₹1.01 L Cr
P/E (TTM)
30.6
P/E (Forward)
20.7
EPS (TTM)
₹39.74
52W Low
₹1,101.00
52W High
₹1,414.90
Dividend Yield
0.65%
Beta
0.25
Price / Book
2.6
Return on Equity
8.84%
Debt / Equity
18.6
Revenue (TTM)
₹33,119 Cr
Gross Margin
50.18%
Operating Margin
4.25%
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has terminated its agreement with Novartis India Limited due to a change in controlling shareholding. The agreement was for the distribution and promotion of select brands in India. The company will continue to commercialize the brands until September 30, 2026.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Ltd. has received U.S. FDA approval for its rituximab biosimilar, a biosimilar to Rituxan, for the U.S. market. The approval further strengthens Dr. Reddy's growing global biosimilars portfolio and advances its biosimilars business in the United States.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh. The inspection was conducted between July 20, 2026, and July 29, 2026. A Form 483 with three observations was issued, which the company will address within the stipulated timeline.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited clarifies recent news item regarding Thailand approval of its antibiotic, NUZOLVENCE, six months after US nod. The company confirms the accuracy of the news headline and provides details on the joint press release with Global Antibiotic Research & Development Partnership Foundation.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has published the transcript of its Q1FY27 earnings call, which was held on July 22, 2026. The company reported a revenue decline of 5.6% and an EBITDA margin of 12.5% for the quarter, due to lower lenalidomide revenues and a provision for inventory and other costs associated with semaglutide API related challenges. The underlying base business, excluding lenalidomide, delivered healthy double-digit growth across all key geographies.
Dr. Reddy's Laboratories Limited
The NSE has sought clarification from Dr. Reddy's Laboratories Limited regarding a news article about the company's antibiotic receiving approval in Thailand, six months after receiving US approval.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange regarding Change in Auditors of the company, approving the appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors for a term of five consecutive years.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the re-appointment of Dr. K P Krishnan as an Independent Director and the appointment of Mr. Srikanth Velamakanni as an Independent Director, and the appointment of M/s Deloitte Haskins & Sells, LLP as Statutory Auditors.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has held its 42nd Annual General Meeting (AGM) on July 23, 2026, through video conferencing. The meeting was attended by 86 members holding 22,25,59,764 shares. The company has submitted the Scrutinizer's Report and voting results to the exchange.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding unaudited financial results for the quarter ended June 30, 2026.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated July 23, 2026, titled 'Intimation of Earnings call recording'. The company has provided a link to the audio recordings of the Earnings call for the quarter ended June 30, 2026, conducted on July 22, 2026.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about Investor Presentation for Q1 FY27 Unaudited Financial Results.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the allotment of Employee Stock Options to eligible employees under the Dr. Reddy's Employees Stock Option Scheme, 2018.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as Independent Registered Public Accounting Firm.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenues of ₹80,705 million, gross profit of ₹37,540 million, and a net profit of ₹4,348 million. The company has also announced the appointment of Dr. Sridevi Khambhampaty as Global Head of Biologics and Senior Management Personnel, and the appointment of M/s Deloitte Haskins & Sells, LLP as the Independent Registered Public Accounting Firm.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about Conference call Transcript regarding Semaglutide Update Call. The company has scaled up the synthetic API manufacturing process, but one of the impurities was found to be out of specifications. A thorough investigation is underway to determine the root cause and implement necessary process improvements.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has announced the release of Q1FY27 results on July 22nd, 2026, after the Board Meeting, along with an earnings call at 19:30 PM IST / 10:00 AM ET.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has made available the audio recording of its conference call held on July 9, 2026, as per SEBI regulations.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has informed the Exchange about an issue with certain batches of semaglutide due to an active pharmaceutical ingredient (API) issue, which will delay commercial supplies until the issue is resolved. The company is investigating the root cause and taking measures to ensure product quality.
Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited has announced that certain batches of semaglutide were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the product, leading to commercial supply delays. The company is investigating the root cause and taking measures to ensure product quality. There is no impact on patient safety or existing regulatory filings.